Stephanie Krebs - 01 Nov 2023 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
Chief Business Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
SNSE
Transactions as of
01 Nov 2023
Net transactions value
$0
Form type
4
Filing time
02 Nov 2023, 16:53:00 UTC
Next filing
23 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNSE Stock Option (Right to Buy) Award $0 +125,000 $0.000000 125,000 01 Nov 2023 Common Stock 125,000 $0.8200 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest and become exercisable as to 25% of the shares underlying the option on November 1, 2024, and the remaining 75% of the shares underlying the Option shall vest and become exercisable in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.